Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1

References

• CiociolaAA, CohenLB, KulkarniP, et al. How drugs are developed and approved by the FDA: current process and future directions. Am J Gastroenterol. 2014;109(5):620–623. doi:10.1038/ajg.2013.40724796999
   PubMed Web of Science ®Google Scholar
• AshburnTT, ThorKB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–683. doi:10.1038/nrd146815286734
   PubMed Web of Science ®Google Scholar
• OpreaTI, BaumanJE, BologaCG, et al. Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg. 2011;8(3–4):61–69. doi:10.1016/j.ddstr.2011.10.00222368688
   PubMedGoogle Scholar
• LangedijkJ, Mantel-TeeuwisseAK, SlijkermanDS, SchutjensM-HDB. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20(8):1027–1034. doi:10.1016/j.drudis.2015.05.00125975957
   PubMed Web of Science ®Google Scholar
• PushpakomS, IorioF, EyersPA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58. doi:10.1038/nrd.2018.16830310233
   PubMed Web of Science ®Google Scholar
• HurleMR, YangL, XieQ, RajpalDK, SanseauP, AgarwalP. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther. 2013;93(4):335–341. doi:10.1038/clpt.2013.123443757
   PubMed Web of Science ®Google Scholar
• ShimJS, LiuJO. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J of Biol Sci. 2014;10(7):654–663. doi:10.7150/ijbs.922425013375
   PubMed Web of Science ®Google Scholar
• LuoH, LiM, YangM, WuF-X, LiY, WangJ. Biomedical data and computational models for drug repositioning: a comprehensive review. Brief Bioinform. 2021;22(2):1604–1619. doi:10.1093/bib/bbz17632043521
   PubMed Web of Science ®Google Scholar
• HernandezJJ, PryszlakM, SmithL, et al. Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front Oncol. 2017;7:273. doi:10.3389/fonc.2017.0027329184849
   PubMed Web of Science ®Google Scholar
• Glantz-GashaiY, MeirsonT, ReuveniE, SamsonAO. Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonance. Drug Des Devel Ther. 2017;11:1803–1813. doi:10.2147/DDDT.S133127
   Web of Science ®Google Scholar
• GelinasC, WhiteE. BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev. 2005;19(11):1263–1268. doi:10.1101/gad.132620515937216
   PubMed Web of Science ®Google Scholar
• ShoreGC, WarrMR. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med. 2008;8(2):138–147. doi:10.2174/15665240878376958018336294
   PubMed Web of Science ®Google Scholar
• BeroukhimR, MermelCH, PorterD, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905. doi:10.1038/nature0882220164920
   PubMed Web of Science ®Google Scholar
• BeekmanAM, HowellLA. Small-molecule and peptide inhibitors of the pro-survival protein Mcl-1. ChemMedChem. 2015;11(8):802–813. doi:10.1002/cmdc.20150049726696548
   PubMed Web of Science ®Google Scholar
• BelmarJ, FesikSW. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther. 2015;145:76–84. doi:10.1016/j.pharmthera.2014.08.00325172548
   PubMed Web of Science ®Google Scholar
• AbidM, SonawaneYA, ContrerasJI, RanaS, NatarajanA. Recent advances in cancer drug development: targeting induced myeloid cell leukemia-1 (Mcl-1) differentiation protein. Curr Med Chem. 2017;24(40):4488–4514. doi:10.2174/092986732466617091209265928901269
   PubMed Web of Science ®Google Scholar
• AshkenaziA, FairbrotherWJ, LeversonJD, SouersAJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017;16(4):273–284. doi:10.1038/nrd.2016.25328209992
   PubMed Web of Science ®Google Scholar
• WanY, DaiN, TangZ, FangH. Small-molecule Mcl-1 inhibitors: emerging anti-tumor agents. Eur J Med Chem. 2018;146:471–482. doi:10.1016/j.ejmech.2018.01.07629407973
   PubMed Web of Science ®Google Scholar
• HirdAW, TronAE. Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacol Ther. 2019;198:59–67. doi:10.1016/j.pharmthera.2019.02.00730790641
   PubMed Web of Science ®Google Scholar
• SenichkinVV, StreletskaiaAY, GorbunovaAS, ZhivotovskyB, KopeinaGS. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 2020;27(2):405–419. doi:10.1038/s41418-019-0486-331907390
   PubMed Web of Science ®Google Scholar
• RasmussenML, TanejaN, NeiningerAC, et al. MCL-1 inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes. iScience. 2020;23(4):101015. doi:10.1016/j.isci.2020.10101532283523
   PubMed Web of Science ®Google Scholar
• BallS, BorthakurG. Apoptosis targeted therapies in acute myeloid leukemia: an update. Expert Rev Hematol. 2020;13(12):1373–1386. doi:10.1080/17474086.2020.185292333205684
   PubMed Web of Science ®Google Scholar
• WoodKC. Overcoming MCL-1-driven adaptive resistance to targeted therapies. Nat Commun. 2020;11(1):531. doi:10.1038/s41467-020-14392-z31988312
   PubMed Web of Science ®Google Scholar
• WishartDS, KnoxC, GuoAC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36(suppl 1):D901–D906. doi:10.1093/nar/gkm95818048412
   PubMed Web of Science ®Google Scholar
• YangLPH, KeamSJ, KeatingGM. Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211–2230. doi:10.2165/00003495-200767150-0000717927285
   PubMed Web of Science ®Google Scholar
• KamiharaY, TakadaK, SatoT, et al. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma. Oncotarget. 2016;7:39. doi:10.18632/oncotarget.11830
   Google Scholar
• MöllerHJ. Risperidone: a review. Expert Opin on Pharmacother. 2005;6(5):803–818. doi:10.1517/14656566.6.5.803
   PubMed Web of Science ®Google Scholar
• DegterevA, LugovskoyA, CardoneM, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol. 2001;3(2):173–182. doi:10.1038/3505508511175750
   PubMed Web of Science ®Google Scholar
• MaierSK, HammondJM. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome. Ann Pharmacother. 2006;40(2):286–289. doi:10.1345/aph.1G17016403850
   PubMed Web of Science ®Google Scholar
• MarkTM, BowmanIA, RossiAC, et al. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leuk Lymphoma. 2014;55(12):2842–2849. doi:10.3109/10428194.2014.89600524576165
   PubMed Web of Science ®Google Scholar
• FriedelHA, BuckleyMM-T. Torasemide: a review of its pharmacological properties and therapeutic potential. Drugs. 1991;41(1):81–103. doi:10.2165/00003495-199141010-000081706990
   PubMed Web of Science ®Google Scholar
• van DelftMF, WeiAH, MasonKD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389–399. doi:10.1016/j.ccr.2006.08.02717097561
   PubMed Web of Science ®Google Scholar
• MeyerB, PetersT. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew Chem Int Ed Engl. 2003;42(8):864–890. doi:10.1002/anie.20039023312596167
   PubMed Web of Science ®Google Scholar
• CalaO, GuillièreF, KrimmI. NMR-based analysis of protein–ligand interactions. Anal Bioanal Chem. 2014;406(4):943–956. doi:10.1007/s00216-013-6931-023591643
   PubMed Web of Science ®Google Scholar
• OrtsJ, GossertAD. Structure determination of protein-ligand complexes by NMR in solution. Methods. 2018;138–139:3–25. doi:10.1016/j.ymeth.2018.01.019
   PubMed Web of Science ®Google Scholar
• Bourafai-AziezA, SebbanM, BenabderrahmaneM, et al. Binding mode of Pyridoclax to myeloid cell leukemia-1 (Mcl-1) revealed by nuclear magnetic resonance spectroscopy, docking and molecular dynamics approaches. J Biomol Struct Dyn. 2020;38(14):4162–4178. doi:10.1080/07391102.2019.168043431612791
   PubMed Web of Science ®Google Scholar
• MoriS, AbeygunawardanaC, JohnsonMO, VanzijlPCM. Improved sensitivity of HSQC spectra of exchanging protons at short interscan delays using a new fast HSQC (FHSQC) detection scheme that avoids water saturation. J Magn Reson B. 1995;108(1):94–98. doi:10.1006/jmrb.1995.11097627436
   PubMedGoogle Scholar
• MarionD, WüthrichK. Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins. Biochem Biophys Res Commun. 1983;113(3):967–974. doi:10.1016/0006-291X(83)91093-86307308
   PubMed Web of Science ®Google Scholar
• LeeW, TonelliM, MarkleyJL. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. Bioinformatics. 2015;31(8):1325–1327. doi:10.1093/bioinformatics/btu83025505092
   PubMed Web of Science ®Google Scholar
• SkinnerSP, FoghRH, BoucherW, RaganTJ, MuredduLG, VuisterGW. CcpNmr AnalysisAssign: a flexible platform for integrated NMR analysis. J Biomol NMR. 2016;66(2):111–124. doi:10.1007/s10858-016-0060-y27663422
   PubMed Web of Science ®Google Scholar
• WaudbyCA, RamosA, CabritaLD, ChristodoulouJ. Two-dimensional NMR lineshape analysis. Sci Rep. 2016;6:24826. doi:10.1038/srep2482627109776
   PubMed Web of Science ®Google Scholar
• WilliamsonMP. Using chemical shift perturbation to characterise ligand binding. Prog Nucl Magn Reson Spectrosc. 2013;73:1–16. doi:10.1016/j.pnmrs.2013.02.00123962882
   PubMed Web of Science ®Google Scholar
• PoulainL, LincetH, DuigouF, et al. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int J Cancer. 1998;78(4):454–463. doi:10.1002/(sici)1097-0215(19981109)78:4<454::aid-ijc11>3.0.co;2-69797134
   PubMed Web of Science ®Google Scholar
• Nikolovska-ColeskaZ, WangR, FangX, et al. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal Biochem. 2004;332:261. doi:10.1016/j.ab.2004.05.05515325294
   PubMed Web of Science ®Google Scholar
• TanakaY, AikawaK, NishidaG, et al. Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins. J Med Chem. 2013;56(23):9635–9645. doi:10.1021/jm401170c24215352
   PubMed Web of Science ®Google Scholar
• SastryGM, AdzhigireyM, DayT, AnnabhimojuR, ShermanW. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27(3):221–234. doi:10.1007/s10822-013-9644-823579614
   PubMed Web of Science ®Google Scholar
• FunH-K, ChantraprommaS, DayanandaAS, YathirajanHS, ThomasS. 4-[3,5-Bis(2-hy-droxy-phen-yl)-1H-1,2,4-triazol-1-yl]benzoic acid dimethyl-formamide monosolvate. Acta Crystallogr Sect E Struct Rep Online. 2012;68(Pt 3):o792–o793. doi:10.1107/S1600536812005806
   Google Scholar
• GroomCR, BrunoIJ, LightfootMP, WardSC. The Cambridge structural database. Acta Cryst B. 2016;72(2):171–179. doi:10.1107/S2052520616003954
   Google Scholar
• GutmanA, EtingerM, GoldringD, PertzikovB, NisnevichG. CCDC 795036: experimental crystal structure determination; 2011.
   Google Scholar
• GrosdidierA, ZoeteV, MichielinO. Fast docking using the CHARMM force field with EADock DSS. J Comput Chem. 2011;32(10):2149–2159. doi:10.1002/jcc.2179721541955
   PubMed Web of Science ®Google Scholar
• GrosdidierA, ZoeteV, MichielinO. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 2011;39:W270–W277. doi:10.1093/nar/gkr36621624888
   PubMed Web of Science ®Google Scholar
• ZoeteV, GrosdidierA, CuendetM, MichielinO. Use of the FACTS solvation model for protein-ligand docking calculations. Application to EADock. J Mol Recognit. 2010;23(5):457–461. doi:10.1002/jmr.101220101644
   PubMed Web of Science ®Google Scholar
• PhillipsJC, BraunR, WangW, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26(16):1781–1802. doi:10.1002/jcc.2028916222654
   PubMed Web of Science ®Google Scholar
• HuangJ, MacKerellAD. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J Comput Chem. 2013;34(25):2135–2145. doi:10.1002/jcc.2335423832629
   PubMed Web of Science ®Google Scholar
• HuangJ, RauscherS, NawrockiG, et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat Methods. 2017;14(1):71–73. doi:10.1038/nmeth.406727819658
   PubMed Web of Science ®Google Scholar
• VanommeslaegheK, HatcherE, AcharyaC, et al. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem. 2009;31(4):671–690. doi:10.1002/jcc.21367
   Web of Science ®Google Scholar
• LeeJ, ChengX, SwailsJM, et al. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. J Chem Theory Comput. 2016;12(1):405–413. doi:10.1021/acs.jctc.5b0093526631602
   PubMed Web of Science ®Google Scholar
• JorgensenWL, JensonC. Temperature dependence of TIP3P, SPC, and TIP4P water from NPT Monte Carlo simulations: seeking temperatures of maximum density. J Comput Chem. 1998;19(10):1179–1186. doi:10.1002/(SICI)1096-987X(19980730)19:10<1179::AID-JCC6>3.0.CO;2-J
   Web of Science ®Google Scholar
• DardenT, YorkD, PedersenL. Particle mesh Ewald: an N ⋅log(N) method for Ewald sums in large systems. J Chem Phys. 1993;98(12):10089–10092. doi:10.1063/1.464397
   Web of Science ®Google Scholar
• HumphreyW, DalkeA, SchultenK. VMD: visual molecular dynamics. J Mol Graph. 1996;14(1):33–38,27–28. doi:10.1016/0263-7855(96)00018-5
   PubMedGoogle Scholar
• ScheurerM, RodenkirchP, SiggelM, et al. PyContact: rapid, customizable, and visual analysis of noncovalent interactions in MD simulations. Biophys J. 2018;114(3):577–583. doi:10.1016/j.bpj.2017.12.00329414703
   PubMed Web of Science ®Google Scholar
• LiuG, PoppeL, AokiK, YamaneH, LewisJ, SzyperskiT. High-quality NMR structure of human anti-apoptotic protein domain Mcl-1(171–327) for cancer drug design. PLoS One. 2014;9(5):e96521. doi:10.1371/journal.pone.009652124789074
   PubMed Web of Science ®Google Scholar
• BissantzC, FolkersG, RognanD. Protein-based virtual screening of chemical databases. 1. evaluation of different docking/scoring combinations. J Med Chem. 2000;43(25):4759–4767. doi:10.1021/jm001044l11123984
   PubMed Web of Science ®Google Scholar
• BenabderrahmaneM, BureauR, Voisin-ChiretAS, Sopkova-de Oliveira SantosJ. Insights into Mcl-1 conformational states and allosteric inhibition mechanism from molecular dynamics simulations, enhanced sampling, and pocket crosstalk analysis. J Chem Inf Model. 2020;60(6):3172–3187. doi:10.1021/acs.jcim.0c0031532392055
   PubMed Web of Science ®Google Scholar
• BrotinE, Meryet-FiguièreM, SimoninK, et al. Bcl-x L and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer. 2010;126(4):885–895. doi:10.1002/ijc.2478719634140
   PubMed Web of Science ®Google Scholar
• SteinhauserS, HeinzU, BartholomäM, WeyhermüllerT, NickH, HegetschweilerK. Complex formation of ICL670 and related ligands with Fe III and Fe II: complex formation of ICL670 and related ligands with Fe III and Fe II. Eur J of Inorg Chem. 2004;2004(21):4177–4192. doi:10.1002/ejic.200400363
   Web of Science ®Google Scholar
• ZhangY, YangH, MaH, et al. Excitation wavelength dependent fluorescence of an ESIPT triazole derivative for amine sensing and anti‐counterfeiting applications. Angew Chem Int Ed Engl. 2019;58(26):8773–8778. doi:10.1002/anie.20190289030900323
   PubMed Web of Science ®Google Scholar
• MadyASA, LiaoC, BajwaN, et al. Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening. Sci Rep. 2018;8(1):10210. doi:10.1038/s41598-018-27899-929976942
   PubMed Web of Science ®Google Scholar
• KrishnamoorthyJ, YuVCK, MokY-K. Auto-FACE: an NMR based binding site mapping program for fast chemical exchange protein-ligand systems. PLoS One. 2010;5(2):e8943. doi:10.1371/journal.pone.000894320174626
   PubMed Web of Science ®Google Scholar